KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) Return on Equity: 2018-2025

Historic Return on Equity for Amneal Pharmaceuticals (AMRX) over the last 7 years, with Sep 2025 value amounting to -0.52%.

  • Amneal Pharmaceuticals' Return on Equity fell 246.00% to -0.52% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.52%, marking a year-over-year decrease of 246.00%. This contributed to the annual value of 1.65% for FY2024, which is 213.00% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Return on Equity of -0.52% as of Q3 2025, which was down 23.59% from -0.42% recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Return on Equity peaked at 5.52% during Q1 2024, and registered a low of -1.62% during Q1 2023.
  • In the last 3 years, Amneal Pharmaceuticals' Return on Equity had a median value of 0.08% in 2023 and averaged 0.67%.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Return on Equity soared by 714bps in 2024, and later tumbled by 579bps in 2025.
  • Quarterly analysis of 5 years shows Amneal Pharmaceuticals' Return on Equity stood at 0.05% in 2021, then crashed by 140bps to -1.35% in 2022, then spiked by 79bps to -0.56% in 2023, then spiked by 129bps to 0.73% in 2024, then plummeted by 246bps to -0.52% in 2025.
  • Its Return on Equity was -0.52% in Q3 2025, compared to -0.42% in Q2 2025 and -0.27% in Q1 2025.